BridgeBio Pharma (NASDAQ:BBIO) Stock Bought Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on March 19th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
• Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

BridgeBio Pharma Stock Up 1.9%

Shares of BBIO traded up $1.38 during trading hours on Thursday, reaching $75.52. The stock had a trading volume of 2,408,540 shares, compared to its average volume of 2,750,313. The company has a market cap of $14.64 billion, a P/E ratio of -19.98 and a beta of 1.09. BridgeBio Pharma, Inc. has a 52 week low of $30.08 and a 52 week high of $84.94. The firm has a 50-day moving average of $71.05 and a 200 day moving average of $68.51.

BridgeBio Pharma (NASDAQ:BBIO) last posted its earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The business had revenue of $154.18 million during the quarter, compared to analysts’ expectations of $150.71 million. During the same quarter in the previous year, the company posted ($1.40) EPS. The company’s quarterly revenue was up 2521.2% on a year-over-year basis. As a group, equities analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BBIO. Sanford C. Bernstein assumed coverage on BridgeBio Pharma in a research report on Thursday, December 11th. They issued an “outperform” rating and a $94.00 price objective for the company. HC Wainwright raised their target price on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Wells Fargo & Company lifted their price target on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the company an “overweight” rating in a research note on Friday, February 13th. Morgan Stanley upped their price target on shares of BridgeBio Pharma from $96.00 to $98.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Finally, Royal Bank Of Canada initiated coverage on shares of BridgeBio Pharma in a report on Thursday. They set an “outperform” rating and a $100.00 price objective on the stock. Twenty-four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.38.

Institutional Investors Weigh In On BridgeBio Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of BBIO. Aster Capital Management DIFC Ltd bought a new position in shares of BridgeBio Pharma during the 3rd quarter worth approximately $31,000. Harvest Fund Management Co. Ltd acquired a new position in BridgeBio Pharma during the third quarter worth $34,000. Jones Financial Companies Lllp acquired a new position in BridgeBio Pharma during the first quarter worth $35,000. First Horizon Corp bought a new position in BridgeBio Pharma in the third quarter valued at $36,000. Finally, Huntington National Bank increased its stake in BridgeBio Pharma by 111.7% in the 3rd quarter. Huntington National Bank now owns 743 shares of the company’s stock valued at $39,000 after buying an additional 392 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

Insider Activity

In related news, Director Andrea Ellis sold 64,921 shares of BridgeBio Pharma stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $64.87, for a total value of $4,211,425.27. Following the sale, the director owned 18,589 shares of the company’s stock, valued at approximately $1,205,868.43. The trade was a 77.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Randal W. Scott sold 10,000 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $75.46, for a total value of $754,600.00. Following the sale, the director owned 11,589 shares in the company, valued at $874,505.94. The trade was a 46.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 197,084 shares of company stock worth $13,649,619. 18.20% of the stock is currently owned by company insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.